BJH - 2018, issue Abstract Book BHS, february 2018
M. Hofmans MD, T. Lammens PhD, S. Bresolin , H. Cavé , C. Flotho , H. Hasle , H. Helsmoortel PhD, M. Van den Heuvel-Eibrink , C. Niemeyer , J. Stary , N. Van Roy PhD, P. Van Vlierberghe PhD, J. Philippé MD, PhD, B. De Moerloose MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
M. Hofmans MD, A. Delie , K. Vandepoele PhD, N. Van Roy PhD, J. Van der Meulen , J. Philippé MD, PhD, I. Moors MD
BJH - 2018, issue Abstract Book BHS, february 2018
A. Delie , P. Vlummens MD, N. Van Roy PhD, F. Offner MD, PhD, T. Kerre MD, PhD
BJH - volume 8, issue 2, march 2017
A-S. De Koninck PharmD, C. Dhooge MD, PhD, B. Denys PharmD, K. Vandepoele PhD, N. Van Roy PhD, M. Hofmans MD, J. Philippé MD, PhD
We describe a case of a four-year-old boy diagnosed with an Early T-cell Precursor Lymphoblastic Leukaemia. This type of leukaemia is recognised as a high-risk subgroup characterised by very early arrest in T-cell differentiation. Early T-cell Precursor Lymphoblastic Leukaemia cases have characteristic gene expression profiles, increased genomic instability and a distinct immature immunophenotype (CD1a–, CD8–, CD5+dim and positivity for at least one marker of stem cell or myeloid lineage). This type of leukaemia is associated with poor prognosis and a poor response to intensive chemotherapy, though this finding is still debated. Our patient displayed an inferior response to induction therapy. The main purpose of this report is to make Belgian physicians aware of this entity and its controversial prognostic significance.
(BELG J HEMATOL 2017;8(2):75–9)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
B. Denys PharmD, J. Van der Meulen , E. de Latter , S. Lefever , T. Rosseel , W. Steyaert , G. Vandercruyssen , I. Rottiers , D. Creytens , J. Van Dorpe , F. Speleman PhD, B. Poppe , N. Van Roy PhD, K. de Leeneer , K. Claes , K. Vandepoele PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
J. Dauw , E. Boone PhD, N. Cardinaels MD, E. Moureau , A. Nijs , F. Nollet PhD, V. Van Hende MD, N. Van Roy PhD, K. Van Eygen MD
BJH - volume 5, issue 4, december 2014
H. Helsmoortel PhD, T. Lammens PhD, N. Van Roy PhD, J. Philippé MD, PhD, P. De Paepe MD, PhD, Y Benoit MD, PhD, F. Speleman PhD, P. Van Vlierberghe PhD, B. De Moerloose MD, PhD
Juvenile myelomonocytic leukaemia is a very rare, aggressive stem cell disorder predominantly affecting infants and young children. Current survival rates are disappointing and the only available curative therapy is haematopoietic stem cell transplantation. Over the last years, intensive research efforts elucidated a plethora of molecular aberrations involved in the pathogenesis of juvenile myelomonocytic leukaemia. Current investigations are mainly directed towards the complete unravelling of the molecular biology behind the disease in order to find more specific drugs. This review will focus on the diagnosis, genomic characterisation and the use of experimental therapies in juvenile myelomonocytic leukaemia.
(BELG J HEMATOL 2014; 5(4): 119–24)
Read more
Top
